Navigation Links
Valeant Pharmaceuticals Reports 2012 Third Quarter Financial Results
Date:11/2/2012

to $1.2 to $1.3 billion due to increased investment in working capital associated with the growth in emerging markets, asset deals which require an investment in working capital post-closing, and plant consolidations including the closing of the Bourdon facility in Canada and the exiting of a legacy Valeant contract manufacturer in Puerto Rico.  Valeant is maintaining prior guidance of total revenue in the range of $3.4 to $3.6 billion.  

Conference Call and Webcast InformationThe Company will host a conference call and a live Internet webcast along with a slide presentation today at 8:00 a.m. ET (5:00 a.m. PT), November 2, 2012 to discuss its third quarter financial results for 2012. The dial-in number to participate on this call is (877) 281-0402, confirmation code 39252322. International callers should dial (631) 813-4869, confirmation code 39252322. A replay will be available approximately two hours following the conclusion of the conference call through November 9, 2012 and can be accessed by dialing (855) 859-2056, or (404) 537-3406, confirmation code 39252322. The live webcast of the conference call may be accessed through the investor relations section of the Company's corporate website at www.valeant.com.

About ValeantValeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Forward-looking StatementsThis press release may contain forward-looking statements, including, but not limited to, statements regarding the closing of the Medicis acquisitions, the approval of efinaconazole (IDP-108), future results and performance and financial guidance, including expected revenue and adjusted cas
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... for solid tumor cancers, announced today that its DCVax-L ... a "Promising Innovative Medicine" (PIM) under the new "Early ... in April 2014.  A PIM is the first step ... the EAMS.  The PIM designation for ...
(Date:9/16/2014)... OKLAHOMA CITY , Sept. 16, 2014 ... biopharmaceutical company developing novel orally active drugs ... existing antibiotics, announced today a $1.4 million ... investing arm of life sciences accelerator Accele ... from i2E, Inc., a nationally recognized private ...
(Date:9/16/2014)... CALGARY, Alberta , Sept. 16, 2014 /PRNewswire/ ... $1.4 billion industry in less than two years, ... along the way. A huge opportunity exists for ... Today, Vivametrica ( http://vivametrica.com/our-video/ ) introduced a first-of-its-kind ... providers based on years of clinical research linking ...
Breaking Medicine Technology:NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3
... DIEGO, June 10, 2011 Volcano Corporation (NASDAQ: ... precision intravascular diagnosis and therapy guidance tools designed to ... said today that it will be participating in the ... on Thursday, June 16. The presentation by ...
... Accuray Incorporated (Nasdaq: ARAY ), a global leader ... have approved the proposed acquisition of TomoTherapy Incorporated (Nasdaq: ... 98 percent of votes cast and 79 percent of shares ... anticipate the closing of the transaction will occur within one ...
Cached Medicine Technology:TomoTherapy Shareholders Approve Accuray Acquisition of TomoTherapy 2TomoTherapy Shareholders Approve Accuray Acquisition of TomoTherapy 3TomoTherapy Shareholders Approve Accuray Acquisition of TomoTherapy 4
(Date:9/16/2014)... who tend to be on the heavy side. Researchers ... found that seven in every ten obese adults underestimate ... this mistake much less often. Mothers of overweight or ... as youngsters misjudge their obese mothers, size, says lead ... a study in the Journal of General Internal ...
(Date:9/16/2014)... the unwitting focus of some of Australia,s best fast ... their performance in competition, thanks to a new training ... Greenwood, from QUT,s Institute of Health and Biomedical Innovation, ... of Excellence for Applied Sport Science Research, has studied ... cricket, long jump, triple jump and pole vault and ...
(Date:9/16/2014)... that compared patient-reported outcomes of a broad set ... single fraction radiation therapy (SFRT) is equally as ... pain, function and quality of life are considered, ... Society for Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. ... pain, function and degree of distress were similar ...
(Date:9/16/2014)... For patients with locally advanced pancreatic cancer, the ... may be a promising treatment option, ultimately allowing ... be an option, according to research presented today ... 56th Annual Meeting. , Surgery is the only ... adenocarcinoma (PDA), the most common type of pancreatic ...
(Date:9/16/2014)... 2014 -- While abnormalities in the adrenergic and ... are thought to play a role in the ... there has been no genetic evidence of this ... at Columbia University,s Mailman School of Public Health ... between the ADRB2 gene and childhood adversity. For ...
Breaking Medicine News(10 mins):Health News:Poor body size judgement can lead to increased tolerance of obesity 2Health News:Getting the jump on competitors: QUT study 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 3
... heart attack and stroke, U.S. officials say , , ... Prilosec with the popular blood thinner Plavix (clopidogrel) can ... at risk for heart attack or stroke, U.S. health ... recently submitted studies by the manufacturer of clopidogrel [Sanofi-Aventis ...
... Seattle Sutton,s Healthy Eating (SSHE) and the ... MCHC affiliated members with meal discounts for SSHE. , ... than 140 hospitals and health care organizations dedicated to improving ... care and in assisting its members in improving the delivery ...
... Mo. Until recently, scientists believed that, following a ... any lost function. After that, patients would be forced ... their remaining abilities. Although this belief has been refuted, ... the current health system is still not giving patients ...
... 17 As we approach Thanksgiving, "Black Friday" and the ... community to please remember the children and families whose lives ... recovery and survival. Among these diseases are leukemia and ... disease, hemophilia and other diseases. , Please take a few ...
... VEGAS, Nov. 17 Ultimat Vodka has recently announced plans ... eliminating world hunger, to help raise awareness and funds for ... "I,m Tired of...," (ITo) Ultimat has created unique wrist ... message "I,m Tired of Hunger." For each bracelet produced, Ultimat ...
... surgery, gunshot victim continues to show improvement , TUESDAY, ... the first facial transplant in the United States can ... her nose, according to a report from her surgeons. ... from the transplanted tissue have integrated with existing tissue, ...
Cached Medicine News:Health News:Heartburn Drugs Can Thwart Popular Blood Thinner 2Health News:Seattle Sutton's Healthy Eating Partners With Metropolitan Chicago Healthcare Council to Provide Discounts for Hospital Patients and Employees 2Health News:Seattle Sutton's Healthy Eating Partners With Metropolitan Chicago Healthcare Council to Provide Discounts for Hospital Patients and Employees 3Health News:Pushing the brain to find new pathways 2Health News:These Patients Need Your Help This Thanksgiving 2Health News:These Patients Need Your Help This Thanksgiving 3Health News:Ultimat Vodka Joins Fight Against Hunger 2Health News:Face Transplant Patient Can Smell, Taste, Breathe Normally 2Health News:Face Transplant Patient Can Smell, Taste, Breathe Normally 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: